Review



recombinant human fgf23  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems recombinant human fgf23
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Recombinant Human Fgf23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12929185-42-0-6
    Average 94 stars, based on 43 article reviews
    recombinant human fgf23 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease"

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    Journal: Journal of Cell Communication and Signaling

    doi: 10.1002/ccs3.70061

    Anti‐GBM disease causes tubular damage and partial renal resistance to FGF23. (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Figure Legend Snippet: Anti‐GBM disease causes tubular damage and partial renal resistance to FGF23. (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.

    Techniques Used: Filtration, Clinical Proteomics, Membrane

    Six‐day course of FGF23 treatment induces renal transcriptional signatures of inflammatory responses and injury. (A) Indicates the number of differentially expressed genes according to experimental comparison in renal bulk RNA‐Seq. (B, C) Depict volcano plots of DEGs above a cutoff of adjusted p < 0.05 and log2‐fold change >1, in the comparison of FGF23 versus vehicle effect in mice with anti‐GBM (B) and the interaction between treatment and disease effect (C). (D–F) Depict significant Reactome gene set enrichment analyses of FGF23 effects in healthy mice (D), mice with anti‐GBM disease (E), and the interaction between treatment and disease effect (F). (G) Depicts a network of ligand–receptor interaction pairs that were significant for FGF23 versus vehicle comparisons in mice with anti‐GBM disease by bulk RNA‐Seq. The ligand–receptor interactions were inferred using R/BulkSignalR. Anti‐GBM, anti‐glomerular basement membrane disease. N = 3 for anti‐GBM groups and n = 4 for healthy groups.
    Figure Legend Snippet: Six‐day course of FGF23 treatment induces renal transcriptional signatures of inflammatory responses and injury. (A) Indicates the number of differentially expressed genes according to experimental comparison in renal bulk RNA‐Seq. (B, C) Depict volcano plots of DEGs above a cutoff of adjusted p < 0.05 and log2‐fold change >1, in the comparison of FGF23 versus vehicle effect in mice with anti‐GBM (B) and the interaction between treatment and disease effect (C). (D–F) Depict significant Reactome gene set enrichment analyses of FGF23 effects in healthy mice (D), mice with anti‐GBM disease (E), and the interaction between treatment and disease effect (F). (G) Depicts a network of ligand–receptor interaction pairs that were significant for FGF23 versus vehicle comparisons in mice with anti‐GBM disease by bulk RNA‐Seq. The ligand–receptor interactions were inferred using R/BulkSignalR. Anti‐GBM, anti‐glomerular basement membrane disease. N = 3 for anti‐GBM groups and n = 4 for healthy groups.

    Techniques Used: Comparison, RNA Sequencing, Membrane

    Bulk RNA‐Seq deconvolution and immunofluorescence staining reveal an FGF23‐driven increase in overall immune cell and macrophage abundance in the kidneys of mice with anti‐GBM disease. (A, B) Depict the annotation of renal cell clusters in the reanalysis of the single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice; see also Supporting Information Figure . (C) Shows a wedding pie plot of the bulk deconvolution of the renal cellular composition according to FGF23 treatment and anti‐GBM disease state, as indicated by labels. Overall renal immune cells and macrophage‐like cells are displayed by bulk deconvolution (D, G) and by immunofluorescence with automated quantification for CD45 (E, F) and F4/80 (H, I). RNA‐Seq: N = 3 for anti‐GBM groups and n = 4 for healthy groups. Immunofluorescence: n = 4 per group. Statistical analysis: two‐way ANOVA. anti‐GBM, anti‐glomerular basement membrane disease; Baso, basophil; CD, collecting duct; d, disease state; DCT, distal convoluted tubule; DLOH, descending limb of Henle; EC, endothelial cell; Granul, granulocyte; i, interaction; IC, intercalated cells; Ly, lymphocyte; Mono, monocyte; Mph, macrophage; NK, natural killer cell; PC, principal cells; PT, proximal tubule; S, segment; t, treatment.
    Figure Legend Snippet: Bulk RNA‐Seq deconvolution and immunofluorescence staining reveal an FGF23‐driven increase in overall immune cell and macrophage abundance in the kidneys of mice with anti‐GBM disease. (A, B) Depict the annotation of renal cell clusters in the reanalysis of the single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice; see also Supporting Information Figure . (C) Shows a wedding pie plot of the bulk deconvolution of the renal cellular composition according to FGF23 treatment and anti‐GBM disease state, as indicated by labels. Overall renal immune cells and macrophage‐like cells are displayed by bulk deconvolution (D, G) and by immunofluorescence with automated quantification for CD45 (E, F) and F4/80 (H, I). RNA‐Seq: N = 3 for anti‐GBM groups and n = 4 for healthy groups. Immunofluorescence: n = 4 per group. Statistical analysis: two‐way ANOVA. anti‐GBM, anti‐glomerular basement membrane disease; Baso, basophil; CD, collecting duct; d, disease state; DCT, distal convoluted tubule; DLOH, descending limb of Henle; EC, endothelial cell; Granul, granulocyte; i, interaction; IC, intercalated cells; Ly, lymphocyte; Mono, monocyte; Mph, macrophage; NK, natural killer cell; PC, principal cells; PT, proximal tubule; S, segment; t, treatment.

    Techniques Used: RNA Sequencing, Immunofluorescence, Staining, Single Cell, Membrane

    Immune protein profiling highlights an increase in circulating soluble tumor necrosis factor receptors induced by FGF23 and anti‐GBM disease in mice. A plasma cytokine protein array shows FGF23 effects in healthy male C57BL/6 mice (A) and in mice treated with nephrotoxic serum to induce anti‐GBM disease (B). The interaction between treatment and disease state (C) and the overall disease effect (D) are shown. (E–F) Depict analyses of soluble TNF receptors 1 and 2 by two‐way ANOVA. d, disease state; t, treatment. N = 4 biologically independent replicates per group. Anti‐GBM, anti‐glomerular basement membrane.
    Figure Legend Snippet: Immune protein profiling highlights an increase in circulating soluble tumor necrosis factor receptors induced by FGF23 and anti‐GBM disease in mice. A plasma cytokine protein array shows FGF23 effects in healthy male C57BL/6 mice (A) and in mice treated with nephrotoxic serum to induce anti‐GBM disease (B). The interaction between treatment and disease state (C) and the overall disease effect (D) are shown. (E–F) Depict analyses of soluble TNF receptors 1 and 2 by two‐way ANOVA. d, disease state; t, treatment. N = 4 biologically independent replicates per group. Anti‐GBM, anti‐glomerular basement membrane.

    Techniques Used: Clinical Proteomics, Protein Array, Membrane

    Renal immune cell recruitment driven by FGF23 excess is exposure time dependent. Renal microarray transcriptome datasets GDS3361 of male Fgf23 transgenic and control mice or sex‐matched Hyp mice of dataset GDS879 (B) underwent bulk deconvolution with reference to single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice and, subsequently, visualization of overall fractions of inferred immune cells and macrophage‐like cells, as indicated. (C) Shows the experimental workflow of experiments with female BALB/c mice undergoing Adriamycin (doxorubicin) nephropathy followed by a single intravenous (IV) injection of FGF23 or vehicle. (D) Shows the urinary albumin/creatinine ratio 7 days after induction of Adriamycin nephropathy. Statistical analysis: two‐way ANOVA. d, disease state. (E–G) Show significant Reactome gene set enrichment analyses of renal FGF23 effects in healthy mice (E), mice with Adriamycin nephropathy (F), and the interaction between treatment and disease effect (G). (H) Depicts the log‐fold change of 8 transcripts with lowest adjusted p ‐value in the interaction analysis of FGF23 effect in diseased versus FGF23 effect in healthy mice in a 2 × 2 factorial design. N = 5 (A), 10 (B), or 4 (C–H) biologically independent replicates per group.
    Figure Legend Snippet: Renal immune cell recruitment driven by FGF23 excess is exposure time dependent. Renal microarray transcriptome datasets GDS3361 of male Fgf23 transgenic and control mice or sex‐matched Hyp mice of dataset GDS879 (B) underwent bulk deconvolution with reference to single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice and, subsequently, visualization of overall fractions of inferred immune cells and macrophage‐like cells, as indicated. (C) Shows the experimental workflow of experiments with female BALB/c mice undergoing Adriamycin (doxorubicin) nephropathy followed by a single intravenous (IV) injection of FGF23 or vehicle. (D) Shows the urinary albumin/creatinine ratio 7 days after induction of Adriamycin nephropathy. Statistical analysis: two‐way ANOVA. d, disease state. (E–G) Show significant Reactome gene set enrichment analyses of renal FGF23 effects in healthy mice (E), mice with Adriamycin nephropathy (F), and the interaction between treatment and disease effect (G). (H) Depicts the log‐fold change of 8 transcripts with lowest adjusted p ‐value in the interaction analysis of FGF23 effect in diseased versus FGF23 effect in healthy mice in a 2 × 2 factorial design. N = 5 (A), 10 (B), or 4 (C–H) biologically independent replicates per group.

    Techniques Used: Microarray, Transgenic Assay, Control, Single Cell, RNA Sequencing, IV Injection

    Intrarenal proinflammatory effects of FGF23 applied ex vivo in PCKS. (A) Male DBA/2J mice underwent dietary treatment with 0.2% adenine for 15 weeks, followed by organ collection and preparation of 300 µm PCKS for a 24‐h treatment with FGF23 or vehicle ex vivo. No disease‐free controls were used for this substudy. (B) Depicts the fibrotic changes in a representative 4 µm section of PCKS stained with hematoxylin and eosin (left scale bar, 500 µm; right, 100 µm). (C) Shows the log‐fold change of upregulated transcripts with the lowest adjusted p ‐value in the FGF23 versus vehicle comparison. (D–F) Show gene set enrichment analyses of FGF23 effects in Reactome (D), WikiPathways (E), and Pathway Interaction Database (F) gene sets. N = 4 biologically independent replicates per group. PCKS, precision‐cut kidney slices.
    Figure Legend Snippet: Intrarenal proinflammatory effects of FGF23 applied ex vivo in PCKS. (A) Male DBA/2J mice underwent dietary treatment with 0.2% adenine for 15 weeks, followed by organ collection and preparation of 300 µm PCKS for a 24‐h treatment with FGF23 or vehicle ex vivo. No disease‐free controls were used for this substudy. (B) Depicts the fibrotic changes in a representative 4 µm section of PCKS stained with hematoxylin and eosin (left scale bar, 500 µm; right, 100 µm). (C) Shows the log‐fold change of upregulated transcripts with the lowest adjusted p ‐value in the FGF23 versus vehicle comparison. (D–F) Show gene set enrichment analyses of FGF23 effects in Reactome (D), WikiPathways (E), and Pathway Interaction Database (F) gene sets. N = 4 biologically independent replicates per group. PCKS, precision‐cut kidney slices.

    Techniques Used: Ex Vivo, Staining, Comparison

    FGF23 is associated with renal immune cell content in human patients with IgA nephropathy. As a reference, single‐nucleus RNA‐Seq data from 5 human kidney biopsies ( GSE199711 ) of 2 healthy controls and 3 patients with chronic kidney disease (CKD) were reanalyzed and annotated (A); see also Supporting Information Figure . 35 patients with IgA nephropathy from the Karolinska Kidney Biopsy Cohort showed an inverse univariable association between circulating FGF23 and measured glomerular filtration rate (GFR) (B). The associations between transcriptome‐inferred renal fibroblasts and immune cells (C–D) or macrophages (E–F) and circulating FGF23 are shown, with adjustment for GFR, 25OH‐vitamin D and parathyroid hormone. (D, F) Show disaggregated data stratified by GFR in CKD stages I–II and III–V.
    Figure Legend Snippet: FGF23 is associated with renal immune cell content in human patients with IgA nephropathy. As a reference, single‐nucleus RNA‐Seq data from 5 human kidney biopsies ( GSE199711 ) of 2 healthy controls and 3 patients with chronic kidney disease (CKD) were reanalyzed and annotated (A); see also Supporting Information Figure . 35 patients with IgA nephropathy from the Karolinska Kidney Biopsy Cohort showed an inverse univariable association between circulating FGF23 and measured glomerular filtration rate (GFR) (B). The associations between transcriptome‐inferred renal fibroblasts and immune cells (C–D) or macrophages (E–F) and circulating FGF23 are shown, with adjustment for GFR, 25OH‐vitamin D and parathyroid hormone. (D, F) Show disaggregated data stratified by GFR in CKD stages I–II and III–V.

    Techniques Used: RNA Sequencing, Filtration

    Related Articles

    Recombinant:

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease
    Article Snippet: .. Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52). .. Mice of the anti‐GBM model and controls were randomly allocated to receive daily intravenous injections of 1 μg of FGF23 suspended in PBS‐BSA 0.1% (Sigma) or PBSA‐BSA 0.1% vehicle starting 1 day after receiving NTS.

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
    Article Snippet: In Vitro Experiments on the Gene Expression and Death of MLO-Y4 Cells Mouse osteocyte cell line MLO-Y4 cells (31) (2 × 105 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na2HPO4/NaH2PO4, pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Article Title: The renal response to FGF23 shifts from phosphaturia towards inflammation in murine kidney disease models
    Article Snippet: .. Treatments with PBS-BSA 0.1% vehicle or recombinant human FGF23 (R&D Systems #100-52) 200ng/mL, followed by harvesting and freeing in 1mL of RNAlater solution (Sigma Aldrich, Saint Louis, Missouri, USA), direct storage at - 80°C, or fixing overnight in tubes containing 4% formaldehyde (Sigma Aldrich, Saint Louis, Missouri, USA). .. Biochemical parameters were analyzed using quantification kits according to the manufacturer’s instructions, including blood urea nitrogen (BUN) by BUN Colorimetric Detection Kit (EIABUN, Thermo Fisher), creatinine by colorimetric detection using a kit (K625, Bio Vision) and phosphate by a colorimetric kit (MAK-030, Merk).

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats
    Article Snippet: Mouse osteocyte cell line MLO-Y4 cells ( ) (2 × 10 5 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO 2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na 2 HPO 4 /NaH 2 PO 4 , pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Article Title: Molecular Interaction of Soluble Klotho with FGF23 in the Pathobiology of Aortic Valve Lesions Induced by Chronic Kidney Disease
    Article Snippet: .. Endotoxin-free recombinant human FGF23 (2604), human Klotho (MAB5334), mouse Klotho (1819), neutralizing antibody against FGF23 (AF2604), and antibodies against YAP (867711) were purchased from R&D Systems, Minneapolis, MN. .. Antibody against intercellular adhesion molecule 1 (ICAM-1, SC8439) was acquired from Santa Cruz Biotechnology, Dallas, TX.

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease
    Article Snippet: In brief, a Compresstome® VF‐310‐0Z Vibrating Microtome (Precisionary Instruments) filled with William’s E Medium GlutaMAX‐I buffer (WME solution, Thermo Fisher) containing 25 mM D‐glucose (Merck) was used to obtain 300 μm kidney slices containing approximately 2/3 cortex and 1/3 medulla. .. The slices were transferred to 12‐well plates and put into 1.5 mL of WME solution at 37°C and 95% oxygen for 20 h. Treatments were performed with PBS‐BSA 0.1% vehicle or recombinant human FGF23 (R&D Systems, #100‐52) at 200 ng/mL, followed by harvesting and freezing in 1 mL of RNAlater solution (Sigma‐Aldrich), direct storage at −80°C, or fixing overnight in tubes containing 4% formaldehyde (Sigma‐Aldrich). .. Biochemical parameters were analyzed using quantification kits according to the manufacturer's instructions, including blood urea nitrogen (BUN) using the BUN Colorimetric Detection Kit (EIABUN, Thermo Fisher), creatinine by colorimetric detection using a kit (K625, BioVision), and phosphate by a colorimetric kit (Cat. MAK‐030, Merck).

    Derivative Assay:

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
    Article Snippet: In Vitro Experiments on the Gene Expression and Death of MLO-Y4 Cells Mouse osteocyte cell line MLO-Y4 cells (31) (2 × 105 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na2HPO4/NaH2PO4, pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats
    Article Snippet: Mouse osteocyte cell line MLO-Y4 cells ( ) (2 × 10 5 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO 2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na 2 HPO 4 /NaH 2 PO 4 , pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Gene Expression:

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
    Article Snippet: In Vitro Experiments on the Gene Expression and Death of MLO-Y4 Cells Mouse osteocyte cell line MLO-Y4 cells (31) (2 × 105 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na2HPO4/NaH2PO4, pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats
    Article Snippet: Mouse osteocyte cell line MLO-Y4 cells ( ) (2 × 10 5 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO 2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na 2 HPO 4 /NaH 2 PO 4 , pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    In Vitro:

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
    Article Snippet: In Vitro Experiments on the Gene Expression and Death of MLO-Y4 Cells Mouse osteocyte cell line MLO-Y4 cells (31) (2 × 105 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na2HPO4/NaH2PO4, pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    Article Title: Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats
    Article Snippet: Mouse osteocyte cell line MLO-Y4 cells ( ) (2 × 10 5 cells; Kerafast, Inc., Boston, MA, USA) were seeded in a T25 flask containing an α-MEM (FUJIFILM Wako Pure Chemical Co.) containing 2.5% fetal bovine serum (Hyclone # SH30396; Cytive, Tokyo, Japan) and 2.5% calf serum (Hyclone # SH30072, Cytive) and then incubated in a 5% CO 2 incubator for 24 hours. .. The dose of human PTH[1-34] (hPTH[1-34]; Merck KGaA, Darmstadt, Germany), Pi (Na 2 HPO 4 /NaH 2 PO 4 , pH 7.4), and recombinant human FGF23 (hFGF23; R&D Systems) administered to MLO-Y4 cells were adjusted to be similar to the serum concentrations of the molecules derived from CKD rats in order to examine the effects of PTH, Pi, and FGF23 on the gene expression of osteocytes in vitro. ..

    other:

    Article Title: High phosphate-induced progressive proximal tubular injury is associated with the activation of Stat3/Kim-1 signaling pathway and macrophage recruitment.
    Article Snippet: Funding information Deutsche Forschungsgemeinschaft (DFG), Grant/Award Number: Li9487/1; Hannover Medical School, Grant/Award Number: HilF/ LifeScience Stiftung München Abstract Dietary phosphate intake in the Western population greatly exceeds the recommended dietary allowance and is linked to enhanced cardiovascular and allcause mortality.. It is unclear whether a chronic high phosphate diet (HPD) causes kidney injury in healthy individuals.. Here, we show that feeding a 2% HPD in C57BL/6N mice for one up to six months resulted in hyperphosphatemia, hyperphosphaturia, increased plasma levels of fibroblast growth factor (FGF) 23, and parathyroid hormone (PTH) compared to mice on a 0.8% phosphate diet.



    Similar Products

    95
    MedChemExpress recombinant fgf23 rfgf23
    FG-4592 lowers iFGF23 level in CKD rats and CKD patients. Parameters measured include ( A ) Serum intact fibroblast growth factor 23 (iFGF23) levels in CKD rats. B Serum total <t>FGF23</t> levels in CKD rats. C Serum iFGF23 levels in CKD patients. D Serum total FGF23 levels in CKD patients. E Scatter plots with linear regression analysis demonstrating a significant correlation between blood urea nitrogen (BUN) and iFGF23 levels in CKD rats. F Scatter plots with linear regression analysis showing a significant correlation between Scr and iFGF23 levels in CKD rats. G Scatter plots with linear regression analysis revealing a significant correlation between iFGF23 levels and the percentage of fibrotic area in the kidney of CKD rats. H Scatter plots with linear regression analysis indicating a significant correlation between iFGF23 levels and Collagen 1 staining intensity in the kidney of CKD rats. I Scatter plots with linear regression analysis illustrating a significant correlation between iFGF23 levels and Fibronectin staining intensity in the kidney of CKD rats. J Scatter plots with linear regression analysis demonstrating a significant correlation between iFGF23 levels and α-SMA staining intensity in the kidney of CKD rats. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Recombinant Fgf23 Rfgf23, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/Recombinant+Human+Basic+Fibroblast+Growth+Factor/pmc12032739-49-21-24
    Average 95 stars, based on 1 article reviews
    recombinant fgf23 rfgf23 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant human fgf23
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Recombinant Human Fgf23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12929185-42-0-6
    Average 94 stars, based on 1 article reviews
    recombinant human fgf23 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    90
    Dawley Inc human recombinant fgf23
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Human Recombinant Fgf23, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/fgf23+c+tail+peptide/10__1161_slash_circulationaha__124__071605-91-24-8
    Average 90 stars, based on 1 article reviews
    human recombinant fgf23 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Dawley Inc ir-labeled human recombinant fgf23
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Ir Labeled Human Recombinant Fgf23, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/fgf23+c+tail+peptide/10__1161_slash_circulationaha__124__071605-59-5-5
    Average 90 stars, based on 1 article reviews
    ir-labeled human recombinant fgf23 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant fgf23 protein
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Recombinant Fgf23 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12216775-118-17-20
    Average 94 stars, based on 1 article reviews
    recombinant fgf23 protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant human arg 179 gln fgf23
    Anti‐GBM disease causes tubular damage and partial renal resistance to <t>FGF23.</t> (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
    Recombinant Human Arg 179 Gln Fgf23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12133299-155-0-22
    Average 94 stars, based on 1 article reviews
    recombinant human arg 179 gln fgf23 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    FG-4592 lowers iFGF23 level in CKD rats and CKD patients. Parameters measured include ( A ) Serum intact fibroblast growth factor 23 (iFGF23) levels in CKD rats. B Serum total FGF23 levels in CKD rats. C Serum iFGF23 levels in CKD patients. D Serum total FGF23 levels in CKD patients. E Scatter plots with linear regression analysis demonstrating a significant correlation between blood urea nitrogen (BUN) and iFGF23 levels in CKD rats. F Scatter plots with linear regression analysis showing a significant correlation between Scr and iFGF23 levels in CKD rats. G Scatter plots with linear regression analysis revealing a significant correlation between iFGF23 levels and the percentage of fibrotic area in the kidney of CKD rats. H Scatter plots with linear regression analysis indicating a significant correlation between iFGF23 levels and Collagen 1 staining intensity in the kidney of CKD rats. I Scatter plots with linear regression analysis illustrating a significant correlation between iFGF23 levels and Fibronectin staining intensity in the kidney of CKD rats. J Scatter plots with linear regression analysis demonstrating a significant correlation between iFGF23 levels and α-SMA staining intensity in the kidney of CKD rats. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Cell Communication and Signaling : CCS

    Article Title: The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

    doi: 10.1186/s12964-025-02175-2

    Figure Lengend Snippet: FG-4592 lowers iFGF23 level in CKD rats and CKD patients. Parameters measured include ( A ) Serum intact fibroblast growth factor 23 (iFGF23) levels in CKD rats. B Serum total FGF23 levels in CKD rats. C Serum iFGF23 levels in CKD patients. D Serum total FGF23 levels in CKD patients. E Scatter plots with linear regression analysis demonstrating a significant correlation between blood urea nitrogen (BUN) and iFGF23 levels in CKD rats. F Scatter plots with linear regression analysis showing a significant correlation between Scr and iFGF23 levels in CKD rats. G Scatter plots with linear regression analysis revealing a significant correlation between iFGF23 levels and the percentage of fibrotic area in the kidney of CKD rats. H Scatter plots with linear regression analysis indicating a significant correlation between iFGF23 levels and Collagen 1 staining intensity in the kidney of CKD rats. I Scatter plots with linear regression analysis illustrating a significant correlation between iFGF23 levels and Fibronectin staining intensity in the kidney of CKD rats. J Scatter plots with linear regression analysis demonstrating a significant correlation between iFGF23 levels and α-SMA staining intensity in the kidney of CKD rats. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: CKD rats were surgically implanted with Alzet osmotic pumps (Durect Corporation, Cupertino, CA) as described previously [ ] and infused with recombinant FGF23 (rFGF23) (MCE, USA) or vehicle (normal saline; VE) for 28 days.

    Techniques: Staining

    The renoprotective effects of FG-4592 were abrogated by FGF23 overexpression. Parameters measured include ( A ) Schematic diagram illustrating the experimental groups of rats: CKD + FG-4592 + vehicle and CKD + FG-4592 + rFGF23. B and C Renal function was assessed by measuring Scr and BUN levels. D mRNA expression levels of Col1a1 , Fn1 , and Acta2 in the renal cortex were quantified using real-time PCR. E Western blot analysis was performed to evaluate the protein expression of Collagen 1 and α-SMA, which reflect the extent of TIF. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as the loading control. F Representative images of PAS staining and the percentage of fibrotic area in kidney tissues. Scale bars: 50 μm. G Representative immunohistochemical images demonstrating the upregulation of Collagen 1 and α-SMA in the CKD + FG-4592 + rFGF23 group. Scale bars: 50 μm. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Cell Communication and Signaling : CCS

    Article Title: The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

    doi: 10.1186/s12964-025-02175-2

    Figure Lengend Snippet: The renoprotective effects of FG-4592 were abrogated by FGF23 overexpression. Parameters measured include ( A ) Schematic diagram illustrating the experimental groups of rats: CKD + FG-4592 + vehicle and CKD + FG-4592 + rFGF23. B and C Renal function was assessed by measuring Scr and BUN levels. D mRNA expression levels of Col1a1 , Fn1 , and Acta2 in the renal cortex were quantified using real-time PCR. E Western blot analysis was performed to evaluate the protein expression of Collagen 1 and α-SMA, which reflect the extent of TIF. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as the loading control. F Representative images of PAS staining and the percentage of fibrotic area in kidney tissues. Scale bars: 50 μm. G Representative immunohistochemical images demonstrating the upregulation of Collagen 1 and α-SMA in the CKD + FG-4592 + rFGF23 group. Scale bars: 50 μm. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: CKD rats were surgically implanted with Alzet osmotic pumps (Durect Corporation, Cupertino, CA) as described previously [ ] and infused with recombinant FGF23 (rFGF23) (MCE, USA) or vehicle (normal saline; VE) for 28 days.

    Techniques: Over Expression, Expressing, Real-time Polymerase Chain Reaction, Western Blot, Control, Staining, Immunohistochemical staining

    iFGF23 mediates FG-4592-induced inhibition of tubular cell fibrogenesis. HK-2 cells were pre-treated with TGF-β1 (10 ng/mL) for 24 h, followed by treatment with recombinant FGF23 (rFGF23, 50 ng/mL) or vehicle for an additional 24 h. Parameters measured include: A COL1A1 mRNA expression levels in HK-2 cells, as determined by quantitative PCR (qPCR). B TGFB1 mRNA expression levels in HK-2 cells, as determined by qPCR. C Collagen 1 protein expression levels in HK-2 cells, as assessed by Western blot analysis. D Schematic illustration of the co-culture system using UMR-106 cells and HK-2 cells in a Transwell setup. E mRNA expression levels of Fn1 , Acta2 , and Col1a1 in HK-2 cells, as quantified by qPCR. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Journal: Cell Communication and Signaling : CCS

    Article Title: The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

    doi: 10.1186/s12964-025-02175-2

    Figure Lengend Snippet: iFGF23 mediates FG-4592-induced inhibition of tubular cell fibrogenesis. HK-2 cells were pre-treated with TGF-β1 (10 ng/mL) for 24 h, followed by treatment with recombinant FGF23 (rFGF23, 50 ng/mL) or vehicle for an additional 24 h. Parameters measured include: A COL1A1 mRNA expression levels in HK-2 cells, as determined by quantitative PCR (qPCR). B TGFB1 mRNA expression levels in HK-2 cells, as determined by qPCR. C Collagen 1 protein expression levels in HK-2 cells, as assessed by Western blot analysis. D Schematic illustration of the co-culture system using UMR-106 cells and HK-2 cells in a Transwell setup. E mRNA expression levels of Fn1 , Acta2 , and Col1a1 in HK-2 cells, as quantified by qPCR. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Article Snippet: CKD rats were surgically implanted with Alzet osmotic pumps (Durect Corporation, Cupertino, CA) as described previously [ ] and infused with recombinant FGF23 (rFGF23) (MCE, USA) or vehicle (normal saline; VE) for 28 days.

    Techniques: Inhibition, Recombinant, Expressing, Real-time Polymerase Chain Reaction, Western Blot, Co-Culture Assay

    FG-4592 ameliorates TIF by inhibiting iFGF23-WNT5A pathway. Parameters measured include ( A ) Hierarchical clustering analysis revealing distinct mRNA expression profiles among the experimental groups. Yellow and blue shades indicate expression levels above and below the relative mean, respectively, across all samples. B Gene Ontology (GO) enrichment analysis. C Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. D and F mRNA and protein expression levels of Wnt5a and β-catenin in the following groups: sham, CKD + vehicle, and CKD + FG-4592. E and G mRNA and protein expression levels of Wnt5a and β-catenin in the following groups: CKD + FG-4592 + vehicle and CKD + FG-4592 + rFGF23. H and I Representative immunohistochemical images showing Wnt5a and β-catenin expression in kidney tissues across different experimental groups. J mRNA expression levels of COL1A1 , ACTA1 , WNT5A , and CTNNB1 in HK-2 cells following WNT5A siRNA interference, as determined by quantitative PCR (qPCR). K Protein expression levels of Collagen 1, Wnt5a, and β-catenin in HK-2 cells after WNT5A siRNA interference, as assessed by Western blot analysis. Scale bars: 50 μm. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Cell Communication and Signaling : CCS

    Article Title: The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

    doi: 10.1186/s12964-025-02175-2

    Figure Lengend Snippet: FG-4592 ameliorates TIF by inhibiting iFGF23-WNT5A pathway. Parameters measured include ( A ) Hierarchical clustering analysis revealing distinct mRNA expression profiles among the experimental groups. Yellow and blue shades indicate expression levels above and below the relative mean, respectively, across all samples. B Gene Ontology (GO) enrichment analysis. C Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. D and F mRNA and protein expression levels of Wnt5a and β-catenin in the following groups: sham, CKD + vehicle, and CKD + FG-4592. E and G mRNA and protein expression levels of Wnt5a and β-catenin in the following groups: CKD + FG-4592 + vehicle and CKD + FG-4592 + rFGF23. H and I Representative immunohistochemical images showing Wnt5a and β-catenin expression in kidney tissues across different experimental groups. J mRNA expression levels of COL1A1 , ACTA1 , WNT5A , and CTNNB1 in HK-2 cells following WNT5A siRNA interference, as determined by quantitative PCR (qPCR). K Protein expression levels of Collagen 1, Wnt5a, and β-catenin in HK-2 cells after WNT5A siRNA interference, as assessed by Western blot analysis. Scale bars: 50 μm. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: CKD rats were surgically implanted with Alzet osmotic pumps (Durect Corporation, Cupertino, CA) as described previously [ ] and infused with recombinant FGF23 (rFGF23) (MCE, USA) or vehicle (normal saline; VE) for 28 days.

    Techniques: Expressing, Immunohistochemical staining, Real-time Polymerase Chain Reaction, Western Blot

    FG-4592 lowers iFGF23 levels through Furin-mediated cleavage. Parameters measured include ( A ) mRNA expression levels of Furin , Galnt3 , and Fam20c in bone tissues from the following groups: sham, CKD + vehicle, and CKD + FG-4592, as determined by quantitative PCR (qPCR). B Protein levels of HIF-1α, Furin, and intact fibroblast growth factor 23 (iFGF23) in bone tissues treated with FG-4592 or vehicle, as assessed by Western blot analysis. C Representative images of hematoxylin and eosin (HE) staining of bone tissues (scale bars: 20 μm), along with IHC staining for HIF-1α and iFGF23 (scale bars: 50 μm) and Furin (scale bars: 100 μm). D UMR-106 cells were pretreated with 10 nM 1,25(OH) 2 D 3 , and the expression of FGF23 mRNA was analyzed using real-time PCR. E Western blot analysis was performed to measure iFGF23 protein expression in UMR-106 cells. Cells were pretreated with indoxyl sulfate (IS, 0.5 mM) or vehicle, followed by treatment with FG-4592 (50 μM) or vehicle for 24 h. F Levels of iFGF23 and total FGF23 in the cell supernatant were quantified using an ELISA assay kit. G Western blot analysis was used to evaluate the protein expression of iFGF23 and Furin in UMR-106 cells. H Motif map of the Furin promoter region, highlighting the HIF-1 binding site. I ChIP assays demonstrated HIF-1 binding to the Furin promoter, which was enhanced by FG-4592 stimulation (50 μM for 24 h). J Protein expression levels of Furin and iFGF23 in UMR-106 cells following Furin siRNA interference, as determined by Western blot analysis. K Levels of iFGF23 and total FGF23 in the cell supernatant were measured using an ELISA assay kit after Furin siRNA interference. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Cell Communication and Signaling : CCS

    Article Title: The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

    doi: 10.1186/s12964-025-02175-2

    Figure Lengend Snippet: FG-4592 lowers iFGF23 levels through Furin-mediated cleavage. Parameters measured include ( A ) mRNA expression levels of Furin , Galnt3 , and Fam20c in bone tissues from the following groups: sham, CKD + vehicle, and CKD + FG-4592, as determined by quantitative PCR (qPCR). B Protein levels of HIF-1α, Furin, and intact fibroblast growth factor 23 (iFGF23) in bone tissues treated with FG-4592 or vehicle, as assessed by Western blot analysis. C Representative images of hematoxylin and eosin (HE) staining of bone tissues (scale bars: 20 μm), along with IHC staining for HIF-1α and iFGF23 (scale bars: 50 μm) and Furin (scale bars: 100 μm). D UMR-106 cells were pretreated with 10 nM 1,25(OH) 2 D 3 , and the expression of FGF23 mRNA was analyzed using real-time PCR. E Western blot analysis was performed to measure iFGF23 protein expression in UMR-106 cells. Cells were pretreated with indoxyl sulfate (IS, 0.5 mM) or vehicle, followed by treatment with FG-4592 (50 μM) or vehicle for 24 h. F Levels of iFGF23 and total FGF23 in the cell supernatant were quantified using an ELISA assay kit. G Western blot analysis was used to evaluate the protein expression of iFGF23 and Furin in UMR-106 cells. H Motif map of the Furin promoter region, highlighting the HIF-1 binding site. I ChIP assays demonstrated HIF-1 binding to the Furin promoter, which was enhanced by FG-4592 stimulation (50 μM for 24 h). J Protein expression levels of Furin and iFGF23 in UMR-106 cells following Furin siRNA interference, as determined by Western blot analysis. K Levels of iFGF23 and total FGF23 in the cell supernatant were measured using an ELISA assay kit after Furin siRNA interference. Data are presented as means ± SD ( n = 5). Statistical significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: CKD rats were surgically implanted with Alzet osmotic pumps (Durect Corporation, Cupertino, CA) as described previously [ ] and infused with recombinant FGF23 (rFGF23) (MCE, USA) or vehicle (normal saline; VE) for 28 days.

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Staining, Immunohistochemistry, Enzyme-linked Immunosorbent Assay, Binding Assay

    Anti‐GBM disease causes tubular damage and partial renal resistance to FGF23. (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Anti‐GBM disease causes tubular damage and partial renal resistance to FGF23. (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: Filtration, Clinical Proteomics, Membrane

    Six‐day course of FGF23 treatment induces renal transcriptional signatures of inflammatory responses and injury. (A) Indicates the number of differentially expressed genes according to experimental comparison in renal bulk RNA‐Seq. (B, C) Depict volcano plots of DEGs above a cutoff of adjusted p < 0.05 and log2‐fold change >1, in the comparison of FGF23 versus vehicle effect in mice with anti‐GBM (B) and the interaction between treatment and disease effect (C). (D–F) Depict significant Reactome gene set enrichment analyses of FGF23 effects in healthy mice (D), mice with anti‐GBM disease (E), and the interaction between treatment and disease effect (F). (G) Depicts a network of ligand–receptor interaction pairs that were significant for FGF23 versus vehicle comparisons in mice with anti‐GBM disease by bulk RNA‐Seq. The ligand–receptor interactions were inferred using R/BulkSignalR. Anti‐GBM, anti‐glomerular basement membrane disease. N = 3 for anti‐GBM groups and n = 4 for healthy groups.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Six‐day course of FGF23 treatment induces renal transcriptional signatures of inflammatory responses and injury. (A) Indicates the number of differentially expressed genes according to experimental comparison in renal bulk RNA‐Seq. (B, C) Depict volcano plots of DEGs above a cutoff of adjusted p < 0.05 and log2‐fold change >1, in the comparison of FGF23 versus vehicle effect in mice with anti‐GBM (B) and the interaction between treatment and disease effect (C). (D–F) Depict significant Reactome gene set enrichment analyses of FGF23 effects in healthy mice (D), mice with anti‐GBM disease (E), and the interaction between treatment and disease effect (F). (G) Depicts a network of ligand–receptor interaction pairs that were significant for FGF23 versus vehicle comparisons in mice with anti‐GBM disease by bulk RNA‐Seq. The ligand–receptor interactions were inferred using R/BulkSignalR. Anti‐GBM, anti‐glomerular basement membrane disease. N = 3 for anti‐GBM groups and n = 4 for healthy groups.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: Comparison, RNA Sequencing, Membrane

    Bulk RNA‐Seq deconvolution and immunofluorescence staining reveal an FGF23‐driven increase in overall immune cell and macrophage abundance in the kidneys of mice with anti‐GBM disease. (A, B) Depict the annotation of renal cell clusters in the reanalysis of the single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice; see also Supporting Information Figure . (C) Shows a wedding pie plot of the bulk deconvolution of the renal cellular composition according to FGF23 treatment and anti‐GBM disease state, as indicated by labels. Overall renal immune cells and macrophage‐like cells are displayed by bulk deconvolution (D, G) and by immunofluorescence with automated quantification for CD45 (E, F) and F4/80 (H, I). RNA‐Seq: N = 3 for anti‐GBM groups and n = 4 for healthy groups. Immunofluorescence: n = 4 per group. Statistical analysis: two‐way ANOVA. anti‐GBM, anti‐glomerular basement membrane disease; Baso, basophil; CD, collecting duct; d, disease state; DCT, distal convoluted tubule; DLOH, descending limb of Henle; EC, endothelial cell; Granul, granulocyte; i, interaction; IC, intercalated cells; Ly, lymphocyte; Mono, monocyte; Mph, macrophage; NK, natural killer cell; PC, principal cells; PT, proximal tubule; S, segment; t, treatment.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Bulk RNA‐Seq deconvolution and immunofluorescence staining reveal an FGF23‐driven increase in overall immune cell and macrophage abundance in the kidneys of mice with anti‐GBM disease. (A, B) Depict the annotation of renal cell clusters in the reanalysis of the single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice; see also Supporting Information Figure . (C) Shows a wedding pie plot of the bulk deconvolution of the renal cellular composition according to FGF23 treatment and anti‐GBM disease state, as indicated by labels. Overall renal immune cells and macrophage‐like cells are displayed by bulk deconvolution (D, G) and by immunofluorescence with automated quantification for CD45 (E, F) and F4/80 (H, I). RNA‐Seq: N = 3 for anti‐GBM groups and n = 4 for healthy groups. Immunofluorescence: n = 4 per group. Statistical analysis: two‐way ANOVA. anti‐GBM, anti‐glomerular basement membrane disease; Baso, basophil; CD, collecting duct; d, disease state; DCT, distal convoluted tubule; DLOH, descending limb of Henle; EC, endothelial cell; Granul, granulocyte; i, interaction; IC, intercalated cells; Ly, lymphocyte; Mono, monocyte; Mph, macrophage; NK, natural killer cell; PC, principal cells; PT, proximal tubule; S, segment; t, treatment.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: RNA Sequencing, Immunofluorescence, Staining, Single Cell, Membrane

    Immune protein profiling highlights an increase in circulating soluble tumor necrosis factor receptors induced by FGF23 and anti‐GBM disease in mice. A plasma cytokine protein array shows FGF23 effects in healthy male C57BL/6 mice (A) and in mice treated with nephrotoxic serum to induce anti‐GBM disease (B). The interaction between treatment and disease state (C) and the overall disease effect (D) are shown. (E–F) Depict analyses of soluble TNF receptors 1 and 2 by two‐way ANOVA. d, disease state; t, treatment. N = 4 biologically independent replicates per group. Anti‐GBM, anti‐glomerular basement membrane.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Immune protein profiling highlights an increase in circulating soluble tumor necrosis factor receptors induced by FGF23 and anti‐GBM disease in mice. A plasma cytokine protein array shows FGF23 effects in healthy male C57BL/6 mice (A) and in mice treated with nephrotoxic serum to induce anti‐GBM disease (B). The interaction between treatment and disease state (C) and the overall disease effect (D) are shown. (E–F) Depict analyses of soluble TNF receptors 1 and 2 by two‐way ANOVA. d, disease state; t, treatment. N = 4 biologically independent replicates per group. Anti‐GBM, anti‐glomerular basement membrane.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: Clinical Proteomics, Protein Array, Membrane

    Renal immune cell recruitment driven by FGF23 excess is exposure time dependent. Renal microarray transcriptome datasets GDS3361 of male Fgf23 transgenic and control mice or sex‐matched Hyp mice of dataset GDS879 (B) underwent bulk deconvolution with reference to single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice and, subsequently, visualization of overall fractions of inferred immune cells and macrophage‐like cells, as indicated. (C) Shows the experimental workflow of experiments with female BALB/c mice undergoing Adriamycin (doxorubicin) nephropathy followed by a single intravenous (IV) injection of FGF23 or vehicle. (D) Shows the urinary albumin/creatinine ratio 7 days after induction of Adriamycin nephropathy. Statistical analysis: two‐way ANOVA. d, disease state. (E–G) Show significant Reactome gene set enrichment analyses of renal FGF23 effects in healthy mice (E), mice with Adriamycin nephropathy (F), and the interaction between treatment and disease effect (G). (H) Depicts the log‐fold change of 8 transcripts with lowest adjusted p ‐value in the interaction analysis of FGF23 effect in diseased versus FGF23 effect in healthy mice in a 2 × 2 factorial design. N = 5 (A), 10 (B), or 4 (C–H) biologically independent replicates per group.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Renal immune cell recruitment driven by FGF23 excess is exposure time dependent. Renal microarray transcriptome datasets GDS3361 of male Fgf23 transgenic and control mice or sex‐matched Hyp mice of dataset GDS879 (B) underwent bulk deconvolution with reference to single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice and, subsequently, visualization of overall fractions of inferred immune cells and macrophage‐like cells, as indicated. (C) Shows the experimental workflow of experiments with female BALB/c mice undergoing Adriamycin (doxorubicin) nephropathy followed by a single intravenous (IV) injection of FGF23 or vehicle. (D) Shows the urinary albumin/creatinine ratio 7 days after induction of Adriamycin nephropathy. Statistical analysis: two‐way ANOVA. d, disease state. (E–G) Show significant Reactome gene set enrichment analyses of renal FGF23 effects in healthy mice (E), mice with Adriamycin nephropathy (F), and the interaction between treatment and disease effect (G). (H) Depicts the log‐fold change of 8 transcripts with lowest adjusted p ‐value in the interaction analysis of FGF23 effect in diseased versus FGF23 effect in healthy mice in a 2 × 2 factorial design. N = 5 (A), 10 (B), or 4 (C–H) biologically independent replicates per group.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: Microarray, Transgenic Assay, Control, Single Cell, RNA Sequencing, IV Injection

    Intrarenal proinflammatory effects of FGF23 applied ex vivo in PCKS. (A) Male DBA/2J mice underwent dietary treatment with 0.2% adenine for 15 weeks, followed by organ collection and preparation of 300 µm PCKS for a 24‐h treatment with FGF23 or vehicle ex vivo. No disease‐free controls were used for this substudy. (B) Depicts the fibrotic changes in a representative 4 µm section of PCKS stained with hematoxylin and eosin (left scale bar, 500 µm; right, 100 µm). (C) Shows the log‐fold change of upregulated transcripts with the lowest adjusted p ‐value in the FGF23 versus vehicle comparison. (D–F) Show gene set enrichment analyses of FGF23 effects in Reactome (D), WikiPathways (E), and Pathway Interaction Database (F) gene sets. N = 4 biologically independent replicates per group. PCKS, precision‐cut kidney slices.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: Intrarenal proinflammatory effects of FGF23 applied ex vivo in PCKS. (A) Male DBA/2J mice underwent dietary treatment with 0.2% adenine for 15 weeks, followed by organ collection and preparation of 300 µm PCKS for a 24‐h treatment with FGF23 or vehicle ex vivo. No disease‐free controls were used for this substudy. (B) Depicts the fibrotic changes in a representative 4 µm section of PCKS stained with hematoxylin and eosin (left scale bar, 500 µm; right, 100 µm). (C) Shows the log‐fold change of upregulated transcripts with the lowest adjusted p ‐value in the FGF23 versus vehicle comparison. (D–F) Show gene set enrichment analyses of FGF23 effects in Reactome (D), WikiPathways (E), and Pathway Interaction Database (F) gene sets. N = 4 biologically independent replicates per group. PCKS, precision‐cut kidney slices.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: Ex Vivo, Staining, Comparison

    FGF23 is associated with renal immune cell content in human patients with IgA nephropathy. As a reference, single‐nucleus RNA‐Seq data from 5 human kidney biopsies ( GSE199711 ) of 2 healthy controls and 3 patients with chronic kidney disease (CKD) were reanalyzed and annotated (A); see also Supporting Information Figure . 35 patients with IgA nephropathy from the Karolinska Kidney Biopsy Cohort showed an inverse univariable association between circulating FGF23 and measured glomerular filtration rate (GFR) (B). The associations between transcriptome‐inferred renal fibroblasts and immune cells (C–D) or macrophages (E–F) and circulating FGF23 are shown, with adjustment for GFR, 25OH‐vitamin D and parathyroid hormone. (D, F) Show disaggregated data stratified by GFR in CKD stages I–II and III–V.

    Journal: Journal of Cell Communication and Signaling

    Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease

    doi: 10.1002/ccs3.70061

    Figure Lengend Snippet: FGF23 is associated with renal immune cell content in human patients with IgA nephropathy. As a reference, single‐nucleus RNA‐Seq data from 5 human kidney biopsies ( GSE199711 ) of 2 healthy controls and 3 patients with chronic kidney disease (CKD) were reanalyzed and annotated (A); see also Supporting Information Figure . 35 patients with IgA nephropathy from the Karolinska Kidney Biopsy Cohort showed an inverse univariable association between circulating FGF23 and measured glomerular filtration rate (GFR) (B). The associations between transcriptome‐inferred renal fibroblasts and immune cells (C–D) or macrophages (E–F) and circulating FGF23 are shown, with adjustment for GFR, 25OH‐vitamin D and parathyroid hormone. (D, F) Show disaggregated data stratified by GFR in CKD stages I–II and III–V.

    Article Snippet: Recombinant human FGF23 was obtained from R&D Systems, Minneapolis, MN, USA, and distributed via Thermo Fisher (Cat. #100‐52).

    Techniques: RNA Sequencing, Filtration